• Markets
  • icon
  • Companies
RCE · ASX

Recce Pharmaceuticals Ltd. (ASX:RCE)

AU$0.6

 -0.015 (-2.459%)
ASX:Live
17/05/2024 04:10:34 PM
HALO Ords HALO Momentum HALO Consensus Value HALO Capital Efficiency GROWTH AUS +3
Consensus Score
/10
Recommend
Target Price
Deviation
Unlock Full Consensus Insights

RCE Overview

RCE Health Scores

Short Term

Mean Revision

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Weak

Earnings

Weak

Growth

Earnings

Neutral

Dividends

Very Strong

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Strong

About RCE

Telephone

Address

Description

Recce Pharmaceuticals Ltd. is engaged in the research and development of pharmaceutical drugs that kill germs. It produces antibiotics that are effective in attacking disease-causing Gram-positive and Gram-negative bacteria. The company was founded on April 11, 2007 and is headquartered in Sydney, Australia.

RCE Price Chart

Key Stats

Market Cap

AU$124.43M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.41 - 0.78

Trade Value (12mth)

AU$23,933.00

1 week

-7.03%

1 month

15.53%

YTD

13.33%

1 year

6.36%

All time high

1.8564800024032593

Key Fundamentals

EPS 3 yr Growth

119.500%

EBITDA Margin

N/A

Operating Cashflow

-$13m

Free Cash Flow Return

-335.00%

ROIC

-345.30%

Interest Coverage

-93.40

Quick Ratio

0.40

Other Data

Shares on Issue (Fully Dilluted)

179m

HALO Sector

Next Company Report Date

30-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.01

RCE Announcements

Latest Announcements

Date Announcements

15 May 24

Ph I/II UTI/Urosepsis Trial Dosing Commenced in Next Cohort

×

Ph I/II UTI/Urosepsis Trial Dosing Commenced in Next Cohort

10 May 24

Application for quotation of securities - RCE

×

Application for quotation of securities - RCE

10 May 24

Cleansing Statement

×

Cleansing Statement

09 May 24

MCRI Pilot Study- Positive Efficacy Data for Lung Infections

×

MCRI Pilot Study- Positive Efficacy Data for Lung Infections

07 May 24

China Patent Granted for RECCE Anti-Infectives

×

China Patent Granted for RECCE Anti-Infectives

26 April 24

Safety Committee Approves High Dose of 4,000mg

×

Safety Committee Approves High Dose of 4,000mg

22 April 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

16 April 24

Recce Completes 5,000 R327 Doses Per Week under GMP

×

Recce Completes 5,000 R327 Doses Per Week under GMP

16 April 24

Application for quotation of securities - RCE

×

Application for quotation of securities - RCE

16 April 24

Cleansing Statement

×

Cleansing Statement

08 April 24

Recce Pharmaceuticals - Business Update

×

Recce Pharmaceuticals - Business Update

03 April 24

Patent Granted in Israel for RECCE Anti-Infectives

×

Patent Granted in Israel for RECCE Anti-Infectives

21 March 24

RECCE Trademark Registered - Canada

×

RECCE Trademark Registered - Canada

15 March 24

Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial

×

Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial

12 March 24

Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial

×

Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial

08 March 24

Recce Receives AUD $11.17m R&D Advance

×

Recce Receives AUD $11.17m R&D Advance

27 February 24

Recce Continues Strategic Partnership with MCRI

×

Recce Continues Strategic Partnership with MCRI

27 February 24

Notification of cessation of securities - RCE

×

Notification of cessation of securities - RCE

27 February 24

Appendix 4D and Interim Financial Report

×

Appendix 4D and Interim Financial Report

26 February 24

Safety Committee Approves Expansion of Ph I/II DFI Trial

×

Safety Committee Approves Expansion of Ph I/II DFI Trial

13 February 24

MoU Clarification Announcement

×

MoU Clarification Announcement

06 February 24

RCE Establishes Strategic Partnership in South-East Asia

×

RCE Establishes Strategic Partnership in South-East Asia

30 January 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

18 January 24

Positive Ph I/II DFI Efficacy Data to Support Site Expansion

×

Positive Ph I/II DFI Efficacy Data to Support Site Expansion

28 December 23

Murdoch Children's R327 Efficacy UTI in-vivo

×

Murdoch Children's R327 Efficacy UTI in-vivo

RCE Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.09 -0.06 -0.07 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.09 -0.06 -0.07 Lock Lock Lock
     Growth % Lock Lock Lock Lock -156.6 27.5 -17.9 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.05 -0.06 -0.07 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.05 -0.05 -0.07 Lock Lock Lock
     Growth % Lock Lock Lock Lock -54.3 -28.9 -17.3 Lock Lock Lock
     Yield % Lock Lock Lock Lock -5.5 -5.8 -11.7 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.12 0.06 -0.01 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.12 0.06 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock 594.2 -52.0 -125.4 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 155 174 176 Lock Lock Lock
Basic m Lock Lock Lock Lock 155 174 176 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 15 14 17 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock -47.2 36.5 -15.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -15 -14 -17 Lock Lock Lock
     Growth % Lock Lock Lock Lock -189.4 7.3 -22.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -15 -14 -17 Lock Lock Lock
     Growth % Lock Lock Lock Lock -184.1 7.9 -22.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -15 -14 -17 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -2 -3 -4 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -14 -11 -13 Lock Lock Lock
     Growth % Lock Lock Lock Lock -213.0 18.7 -19.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -8 -9 -13 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 26 0 3 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -8 -9 -13 Lock Lock Lock
     Growth % Lock Lock Lock Lock -108.0 -14.1 -40.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 21 12 2 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 22 13 3 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -21 -12 -1 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 1 3 5 Lock Lock Lock
Equity $m Lock Lock Lock Lock 21 10 -3 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 21 10 -2 Lock Lock Lock
     Growth % Lock Lock Lock Lock 787.2 -51.0 -124.7 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -62.3 -87.0 -511.7 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -65.9 -109.2 505.2 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -133.5 -92.0 -444.4 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -118.4 -71.9 -345.3 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -68.8 -58.9 -335.0 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock -1,241.2 -1,170.8 -93.4 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 1.4 0.8 0.1 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -101.2 -114.4 50.6 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 19.6 5.0 0.4 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 19.6 5.0 0.4 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 98.5 95.1 80.2 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -728.6 -368.2 -261.6 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -62.3 -87.0 -511.7 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.3 -1.0 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -65.9 -109.2 505.2 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -65.9 -109.2 505.2 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 399.3 941.9 1,202.2 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -399.3 -941.9 -1,202.2 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

%

DPSg

%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.01%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

RCE Shortsell

Frequently Asked Questions

The current share price of Recce Pharmaceuticals Ltd. (RCE:ASX) is AU$0.6.
The 52-week high share price for Recce Pharmaceuticals Ltd. (RCE:ASX) is AU$0.78.
The 52-week low share price for Recce Pharmaceuticals Ltd. (RCE:ASX)? is AU$0.41.
Recce Pharmaceuticals Ltd. (RCE:ASX) does not pay a dividend.
Recce Pharmaceuticals Ltd. (RCE:ASX) does not pay a dividend.
Recce Pharmaceuticals Ltd. (RCE:ASX) does not offer franking credits.
Recce Pharmaceuticals Ltd. (RCE:ASX) is classified in the Healthcare.
The current P/E ratio for Recce Pharmaceuticals Ltd. (RCE:ASX) is .